Item 6 of the Schedule 13D is amended and supplemented as follows: The information included in Item 4 above is incorporated by reference into this Item 6. Credit Agreement The Second Amendment, among other things, provides for the issuance of the Convertible Note (in lieu of the non-convertible promissory note previously contemplated by the Credit Agreement) and an additional loan to the Borrower in the amount of $5,000,000. The Second Amendment also provides that any conversion of principal under the Convertible Note will be treated as an optional prepayment of the principal amount so converted, and any related prepayment premium with respect to the converted principal amount will be satisfied through the issuance of ADSs as contemplated by the Convertible Note. Pursuant to the Credit Amendment, accrued and unpaid interest through the date of the Credit Amendment was paid in kind by adding the amount of such interest (the "PIK Interest") to the outstanding principal amount for the term loans thereunder. Accrued and unpaid interest (other than the PIK Interest) through and including each applicable conversion date remains payable in cash on the next interest payment date (or earlier, as provided in the Credit Agreement) and, except in respect of the PIK Interest, interest payment obligations are not convertible into ADSs, and the conversion of principal under the Convertible Note will not be applied to reduce the amount of accrued and unpaid interest (other than the PIK Interest). Pursuant to the Second Amendment, the Company agreed to reserve from its authorized Ordinary Shares a sufficient number of Ordinary Shares for purposes of enabling the Company to issue ADSs pursuant to the Notes (without regard to the Beneficial Ownership Cap. The Company and Credit Fund III also agreed that the Company would not provide Credit Fund III or its affiliates with any Inside Information (as defined in the Second Amendment) without the express prior written consent of the Credit Fund III, subject to limited exceptions in respect of a default (or circumstances that would give rise to a default) under the Credit Agreement. The foregoing summary of the Credit Amendment is not complete and is qualified in its entirety by reference to the full text thereof, which is filed or incorporated by reference as Exhibit 6 to this Schedule 13D. Convertible Note The Convertible Note provides that the holder thereof may, at any time and from time to time, convert up to $60,000,000 aggregate principal amount of the Convertible Note (the "Conversion Cap") into ADSs of the Issuer at a conversion price equal to the greater of (x) 97% of the volume weighted average price VWAP per ADS on the applicable pricing date and (y) $1.03 per ADS (the "Floor Price"). The Floor Price is subject to adjustment to reflect any share split, share dividend, share consolidation, change in par value or any similar event or transaction in respect of the Ordinary Shares that results in a change in the number of Ordinary Shares represented by each ADS or results in the issuance of additional ADSs or a requirement to surrender outstanding ADSs to be exchanged for new ADSs in respect of a different number of Ordinary Shares. The Convertible Note also provides for customary adjustments in the event of certain recapitalizations, reorganizations, and mergers. The Convertible Note restricts the conversion thereof to the extent that, upon such conversion, the number of the Issuer's Ordinary Shares then beneficially owned by the holder and its "Attribution Parties" (as defined in the Convertible Note), including its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group," would exceed 9.9% of the total number of Ordinary Shares then outstanding (the "Beneficial Ownership Cap"). The Convertible Note also contains covenants on the part of the Issuer, including a covenant that requires the Issuer to maintain sufficient authorized and unissued Ordinary Shares to effect the full exercise of the holder's conversion rights, without giving effect to the Beneficial Ownership Cap. The foregoing summary of the Convertible Note is not complete and is qualified in its entirety by reference to the full text thereof, the form of which is filed or incorporated by reference as Exhibit 7 to this Schedule 13D. Conversion Rights Agreement The Conversion Rights Agreement provides for the satisfaction of TRIB B's outstanding Milestone Payment Obligation and Contingent Payment Obligation, at Credit Fund II's election, by converting either such obligation (in whole or in part) into ADSs of the Issuer from time to time at a conversion price equal to the greater of (x) 97% of the volume weighted average price (VWAP) per ADS on the applicable pricing date and (y) the Floor Price. The Floor Price is subject to adjustment to reflect any share split, share dividend, share consolidation, change in par value or any similar event or transaction in respect of the Ordinary Shares that results in a change in the number of Ordinary Shares represented by each ADS or results in the issuance of additional ADSs or a requirement to surrender outstanding ADSs to be exchanged for new ADSs in respect of a different number of Ordinary Shares. The Conversion Rights Agreement also provides for customary adjustments in the event of certain recapitalizations, reorganizations, and mergers. The Conversion Rights Agreement restricts the conversion of the Milestone Payment Obligation and the Contingent Payment Obligation to the extent that, upon such conversion, the number of shares of the Issuer's Ordinary Shares then beneficially owned by the holder and its "Attribution Parties" (as defined in the Conversion Rights Agreement) including its affiliates and any other person or entities with which such holder would constitute a Section 13(d) "group," would exceed the Beneficial Ownership Cap. The Conversion Rights Agreement contains covenants on the part of the Issuer, including a covenant that requires the Issuer to maintain sufficient authorized but unissued Ordinary Shares to effect the full exercise of the holder's conversion rights, without giving effect to the Beneficial Ownership Cap. The Company and Credit Fund II also agreed that the Company would not provide Credit Fund II or its affiliates with any Inside Information (as defined in the Conversion Rights Agreement) without the express prior written consent of the Credit Fund II, subject to limited exceptions. The foregoing summary of the Conversion Rights Agreement is not complete and is qualified in its entirety by reference to the full text thereof, which is filed or incorporated by reference as Exhibit 8 to this Schedule 13D. Deed Poll As set forth above, each of the Convertible Note and the Conversion Rights Agreement includes a Beneficial Ownership Cap. Each of the Convertible Note and the Conversion Rights Agreement further provides that any purported conversion under the Convertible Note or the Conversion Rights Agreement in violation of the Beneficial Ownership Cap will be null and void and treated as if never made (and that no party will have any voting rights in respect of any ADSs issued in violation of the Beneficial Ownership Cap). In furtherance of such limitations, each of Credit Fund III and Credit Fund II entered into a Deed Poll, dated December 22, 2025, which provides that neither Fund, nor any of their respective Attribution Parties, will have any voting rights (or be entitled to receive notice of or to attend or vote at any meeting) with respect to any ADSs issued in excess of the Beneficial Ownership Cap. The foregoing summary of the Deed Poll is not complete and is qualified in its entirety by reference to the full text thereof, which is filed or incorporated by reference as Exhibit 9 to this Schedule 13D. Registration Rights Agreement Pursuant to the Registration Rights Agreement, the Issuer is required to prepare and file with the SEC on or prior to January 14, 2025 (the "Filing Deadline") a resale registration statement (the "Registration Statement") with respect to (i) any ADSs issued or issuable upon conversion of, or otherwise pursuant to or in respect of, the Convertible Note (without giving effect to the Beneficial Ownership Cap) (the "Conversion Shares"), (ii) any ADSs issued or issuable upon exercise of the conversion rights under the Conversion Rights Agreement (without giving effect to the Beneficial Ownership Cap) (the "Conversion Right Shares"), (iii) the Ordinary Shares underlying the Conversion Shares and the Conversion Right Shares and (iv) any securities issued or issuable upon any share split, share dividend, change in par value, recapitalization, reorganization, reclassification or similar event in respect of ADSs or the Ordinary Shares (including, for the avoidance of doubt, any such transaction that adjusts the number of Ordinary Shares underlying the ADSs) (the "Registrable Securities"). The Registration Rights Agreement provides that the number of ADSs and corresponding Ordinary Shares initially included in such Registration Statement will be 55,890,900, subject to adjustment for any Stock Event occurring prior to the effective date of such Registration Statement (the "Initial Amount"). The Issuer also agreed to file additional Registration Statements covering the resale of all remaining Registrable Securities to the extent in excess of the Initial Amount (or the amount of Registrable Securities otherwise included in the Registration Statement); provided, that the Issuer shall not be required to include in any Registration Statement a number of ADSs that, when multiplied by the VWAP for the ADSs on the Trading Day (as defined in the Registration Rights Agreement) immediately prior to the date the Issuer first knows, or reasonably should have known, that such additional Registration Statement is required, would exceed $50,000,000. The Issuer agreed to cause the Registration Statement to be declared effective by the SEC within 60 calendar days of the Filing Deadline, or, if earlier, five (5) trading days after the Issuer is first notified by the SEC that such Registration Statement will not be reviewed or is no longer subject to review and comment. The foregoing summary of the Registration Rights Agreement is not complete and is qualified in its entirety by reference to the full text thereof, the form of which is filed or incorporated by reference as Exhibit 10 to this Schedule 13D.

Item 7 of the Schedule 13D is amended and supplemented as follows: Exhibit 6 Second Amendment to Credit Agreement, dated as of December 22, 2025, by and among Trinity Biotech PLC, Trinity Biotech, Inc., Fitzgerald Industries International, Inc., Clark Laboratories, Inc. (D/B/A Trinity Biotech (USA)), Biopool U.S., Inc. (D/B/A Trinity Biotech Distribution), Primus Corporation, Mardx Diagnostics, Inc. and Immco Diagnostics, Inc. as borrowers, Trinity Biotech PLC and Certain of its Subsidiaries as Guarantors and Perceptive Credit Holdings III, LP, as Administrative Agent (incorporated by reference Exhibit 99.1 to the Company's report on Form 6-K filed with the Securities and Exchange Commission on December 23, 2025). Exhibit 7 Senior Convertible Note, dated as of December 22, 2025, by and among Trinity Biotech PLC, Trinity Biotech, Inc., Fitzgerald Industries International, Inc., Clark Laboratories, Inc. (D/B/A Trinity Biotech (USA)), Biopool U.S., Inc. (D/B/A Trinity Biotech Distribution), Primus Corporation, Mardx Diagnostics, Inc. and Immco Diagnostics, Inc. and Perceptive Credit Holdings III, LP (incorporated by reference Exhibit 99.2 to the Company's report on Form 6-K filed with the Securities and Exchange Commission on December 23, 2025). Exhibit 8 Conversion Rights Agreement, dated as of December 22, 2025, by and among Trinity Biotech PLC, TRIB Biosensors Inc. and Perceptive Credit Holdings II, LP (incorporated by reference Exhibit 99.3 to the Company's report on Form 6-K filed with the Securities and Exchange Commission on December 23, 2025) Exhibit 9 Deed Poll, dated December 22, 2025, made by Perceptive Credit Holdings III, L.P. and Perceptive Credit Holdings II, L.P. Exhibit 10 Registration Rights Agreement, dated as December 22, 2025, by and among Trinity Biotech PLC, Perceptive Credit Holdings III, L.P. and Perceptive Credit Holdings II, LP (incorporated by reference Exhibit 99.4 to the Company's report on Form 6-K filed with the Securities and Exchange Commission on December 23, 2025)